Ingersoll Rand (IR) Q2 2026 Earnings Call Transcript
Ingersoll Rand (IR) reported Q2 2026 revenue of $2,048.8 million, up 9% YoY, with organic revenue growth of 4.1%. Adjusted EBITDA was $519.9 million, up 2%, while margin fell 160 bps to 25.4%. Adjusted EPS rose 7% to $0.86. The company raised full-year 2026 revenue guidance to 4.5% to 6.5% growth and maintained adjusted EBITDA guidance at $2.13B to $2.19B.
How this was made

The 30-second read
Why it matters
Key trading inputs are the guidance update (revenue up, EBITDA maintained), margin bridge drivers (China inflation, corporate costs), and demand signals (orders up, early-July conversion). Capital allocation items (M&A deployed, credit rating upgrade, insurance recovery) add balance-sheet support but do not fully offset margin concerns.
Market read
Traders will likely reprice IR around the combination of raised revenue guidance, maintained adjusted EBITDA outlook, and explicit regional margin headwinds.
What to watch
The transcript flags delayed long-cycle project conversion in Europe and delayed Middle East project activity; traders may underweight how these timing issues could swing quarterly orders and margins.
Background
This is a transcript-style summary of Ingersoll Rand’s Q2 2026 earnings call, including segment performance, orders, cash flow, liquidity, and full-year guidance.
Ticker impact
Ingersoll Rand reported Q2 2026 results and raised full-year revenue guidance to 4.5% to 6.5%, with EPS guidance $3.45 to $3.57.
Likely choppy post-call trading, with upside bias if investors focus on order momentum and guidance raise, offset by concern over China pricing and margin pressure.
The article discloses multiple decision-relevant datapoints: revenue guidance midpoint +200 bps, maintained adjusted EBITDA range, and explicit margin drivers (China inflation, higher corporate costs) plus order conversion momentum in early July.
Market effects
Industrial equipment and industrial tech demand read-through may improve if investors believe order conversion and Life Sciences exposure are sustaining growth.
China pricing/inflation headwinds are explicitly cited as a margin drag, which can influence regional sentiment for industrials with China exposure.
M&A and balance-sheet flexibility signals (credit rating upgrade, insurance recovery) can affect financing and risk appetite across industrials.
Counterpoint
The guidance raise may be more about timing and order conversion than underlying margin resilience, so upside could fade if China pricing remains pressured into 2H.
Key entities
- companyIngersoll Rand Inc.
Reported Q2 2026 results and updated full-year 2026 guidance, citing margin pressure from China inflation and order momentum from long-cycle conversion.
- executiveVicente Reynal
CEO who discussed order timing impacts in Europe and project delays in the Middle East, and reiterated funnel conversion into orders.
- executiveVikram Kini
CFO who cited the adjusted EBITDA margin decline drivers and a Moody’s one-notch credit rating upgrade to Baa1.



